KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBT (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBT for 15 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 107.25% to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$49.0 million, a 150.1% decrease, with the full-year FY2025 number at -$49.0 million, down 150.1% from a year prior.
  • EBT was -$1.9 million for Q4 2025 at Supernus Pharmaceuticals, up from -$58.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $44.9 million in Q3 2024 to a low of -$58.0 million in Q3 2025.
  • A 5-year average of $9.3 million and a median of $10.4 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: surged 2564.85% in 2024, then tumbled 2499.59% in 2025.
  • Supernus Pharmaceuticals' EBT stood at $2.1 million in 2021, then surged by 1613.31% to $35.1 million in 2022, then tumbled by 97.18% to $990000.0 in 2023, then soared by 2564.85% to $26.4 million in 2024, then tumbled by 107.25% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBT are -$1.9 million (Q4 2025), -$58.0 million (Q3 2025), and $16.7 million (Q2 2025).